Internship

Intern – Environmental Health & Safety

Ehs

Confirmed live in the last 24 hours

Cytokinetics

Cytokinetics

501-1,000 employees

Develops drugs for muscle function disorders

Biotechnology
Healthcare

Compensation Overview

$22 - $45Hourly

San Bruno, CA, USA

Category
Lab & Research
Environmental Sciences

You match the following Cytokinetics's candidate preferences

Employers are more likely to interview you if you match these preferences:

Degree
Experience
Requirements
  • Currently enrolled in university, pursuing a Bachelor’s or Master’s Degree in Occupational Health & Safety, Public Heath, Industrial Safety, Industrial Hygiene, Environmental Engineering, Environmental Sciences, Chemical Engineering, Biological Sciences, or a related field
  • Strong analytical, quantitative, and problem-solving skills
  • Excellent communication and interpersonal skills
  • Ability to work independently and as part of a team
  • Basic knowledge of EHS regulations and standards is a plus
  • Proficiency in Microsoft Office Suite (Word, Excel, PowerPoint), Smart Sheet
Responsibilities
  • Support EHS Program Implementation by assisting with the development and implementation of EHS policies and procedures
  • Help ensure compliance with OSHA, EPA, and other relevant regulations by maintaining records and assisting in audits and inspections
  • Assist with the documentation and reporting of workplace incidents, near misses, and corrective actions
  • Support with updating EHS training content and employee training profiles
  • Help track and analyze EHS metrics, including incidents, safety observations, and waste management, and assist with preparing reports
  • Assist in performing risk assessments to identify potential hazards and implement measures to mitigate them
  • Assist in the development of EHS communications
  • Support ergonomic workspace evaluations
  • Assist with sustainability projects and initiatives
Desired Qualifications
  • Basic knowledge of EHS regulations and standards is a plus

Cytokinetics focuses on developing medicines that improve muscle function for patients with cardiovascular and neuromuscular diseases. Their products are small molecule drugs designed to either enhance or inhibit muscle function, tailored to specific therapeutic needs. The company has a range of drugs in clinical trials, including omecamtiv mecarbil and reldesemtiv, aimed at treating conditions like heart failure, hypertrophic cardiomyopathy, amyotrophic lateral sclerosis, and spinal muscular atrophy. Unlike many competitors, Cytokinetics emphasizes rigorous scientific research and has conducted over 50 clinical trials to ensure the effectiveness of its treatments. The goal is to bring new therapies to market that address the unmet needs of patients suffering from debilitating muscle-related conditions.

Company Stage

IPO

Total Funding

$58.4M

Headquarters

South San Francisco, California

Founded

1998

Growth & Insights
Headcount

6 month growth

-1%

1 year growth

-5%

2 year growth

-2%
Simplify Jobs

Simplify's Take

What believers are saying

  • Recent investments indicate strong interest in muscle activators and inhibitors.
  • Strategic partnerships, like with Sanofi, expand market reach and potential revenue.
  • Significant funding from Royalty Pharma supports commercial launch and R&D advancements.

What critics are saying

  • Increased competition could impact market share and profitability.
  • Potential delays in clinical trials could hinder drug commercialization.
  • Dependence on strategic partnerships may expose Cytokinetics to risks if challenges arise.

What makes Cytokinetics unique

  • Cytokinetics focuses on muscle activators and inhibitors for cardiovascular and neuromuscular diseases.
  • The company has a robust pipeline including omecamtiv mecarbil and aficamten.
  • Cytokinetics engages in strategic partnerships, like with Sanofi, to expand market reach.

Help us improve and share your feedback! Did you find this helpful?